NasdaqGM:IIN

Stock Analysis Report

Executive Summary

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally.

Snowflake

Fundamentals

Flawless balance sheet with reasonable growth potential.

Share Price & News

How has IntriCon's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.5%

IIN

1.9%

US Medical Equipment

0.5%

US Market


1 Year Return

-52.3%

IIN

15.6%

US Medical Equipment

6.8%

US Market

Return vs Industry: IIN underperformed the US Medical Equipment industry which returned 15.6% over the past year.

Return vs Market: IIN underperformed the US Market which returned 6.8% over the past year.


Shareholder returns

IINIndustryMarket
7 Day3.5%1.9%0.5%
30 Day0.8%-2.1%-0.8%
90 Day27.0%-0.4%-0.9%
1 Year-52.3%-52.3%16.6%15.6%9.2%6.8%
3 Year238.7%238.7%72.2%67.0%45.6%36.2%
5 Year270.9%270.9%125.9%100.9%63.2%45.4%

Price Volatility Vs. Market

How volatile is IntriCon's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is IntriCon undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IIN ($21.51) is trading below our estimate of fair value ($44.61)

Significantly Below Fair Value: IIN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IIN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: IIN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IIN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IIN is good value based on its PB Ratio (2.1x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is IntriCon forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

83.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IIN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: IIN is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: IIN's loss is forecast to worsen by 0% next year.

Revenue vs Market: IIN's revenue (13% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: IIN's revenue (13% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IIN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has IntriCon performed over the past 5 years?

12.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IIN is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare IIN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IIN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: IIN has a negative Return on Equity (-0.38%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: IIN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: IIN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is IntriCon's financial position?


Financial Position Analysis

Short Term Liabilities: IIN's short term assets ($66.5M) exceeds its short term liabilities ($22.0M)

Long Term Liabilities: IIN's short term assets (66.5M) exceeds its long term liabilities (5.4M)


Debt to Equity History and Analysis

Debt Level: IIN is debt free.

Reducing Debt: IIN has no debt compared to 5 years ago when its debt to equity ratio was 48.2%.

Debt Coverage: IIN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: IIN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: IIN has a high level of physical assets or inventory.

Debt Coverage by Assets: IIN's debt is not covered by short term assets (assets are -7.4834063208201E+16x debt).


Next Steps

Dividend

What is IntriCon's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate IIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IIN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IIN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IIN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IIN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of IntriCon's salary, the management and board of directors tenure and is there insider trading?

21.1yrs

Average management tenure


CEO

Mark Gorder (72yo)

18.5yrs

Tenure

US$937,868

Compensation

Mr. Mark S. Gorder has been the Chief Executive Officer and President of Intricon Corp., an affiliate of IntriCon Tibbetts Corporation since April 2001. He has been a Director of Intricon Corp., since Janu ...


CEO Compensation Analysis

Compensation vs. Market: Mark's total compensation ($USD937.87K) is about average for companies of similar size in the US market ($USD1.16M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

21.1yrs

Average Tenure

60yo

Average Age

Experienced Management: IIN's management team is seasoned and experienced (21.1 years average tenure).


Board Age and Tenure

10.3yrs

Average Tenure

71.5yo

Average Age

Experienced Board: IIN's board of directors are seasoned and experienced ( 10.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$86,08801 Oct 19
GAMCO Investors, Inc.
EntityCompany
Shares5,500
Max PriceUS$20.66
BuyUS$1,519,62201 Oct 19
GAMCO Investors, Inc.
EntityCompany
Shares77,100
Max PriceUS$21.83
SellUS$029 Aug 19
GAMCO Investors, Inc.
EntityCompany
Shares2,200
Max PriceUS$20.22
BuyUS$305,46229 Aug 19
Teton Advisors, Inc
EntityCompany
Shares17,045
Max PriceUS$18.13
BuyUS$131,29029 Aug 19
Gabelli Foundation Inc, Endowment Arm
EntityCompany
Shares7,000
Max PriceUS$21.95
BuyUS$407,61929 Aug 19
GAMCO Investors, Inc.
EntityCompany
Shares215,770
Max PriceUS$23.48

Ownership Breakdown


Management Team

  • Mark Gorder (72yo)

    CEO, President & Director

    • Tenure: 18.5yrs
    • Compensation: US$937.87k
  • Michael Geraci (60yo)

    Senior Vice President of Sales & Marketing

    • Tenure: 24.8yrs
    • Compensation: US$519.07k
  • Dennis Gonsior (60yo)

    Senior Vice President of Global Operations

    • Tenure: 23.8yrs
    • Compensation: US$495.14k
  • J. Longval (42yo)

    Executive VP

    • Tenure: 13.3yrs
    • Compensation: US$520.00k
  • Cari Sather

    Director of Human Resources

    • Tenure: 0yrs

Board Members

  • Mark Gorder (72yo)

    CEO, President & Director

    • Tenure: 18.5yrs
    • Compensation: US$937.87k
  • Nicholas Giordano (76yo)

    Director

    • Tenure: 18.8yrs
    • Compensation: US$122.50k
  • Ray Huggenberger (60yo)

    Director

    • Tenure: 0.4yrs
  • Robert Masucci (81yo)

    Director

    • Tenure: 17.7yrs
    • Compensation: US$120.00k
  • Philip Smith (51yo)

    Chairman of the Board

    • Tenure: 0.4yrs
    • Compensation: US$109.25k
  • Philip Seamon (71yo)

    Director Emeritus

    • Tenure: 2.8yrs
    • Compensation: US$104.00k

Company Information

IntriCon Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IntriCon Corporation
  • Ticker: IIN
  • Exchange: NasdaqGM
  • Founded: 1930
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$188.392m
  • Shares outstanding: 8.76m
  • Website: https://www.intricon.com

Number of Employees


Location

  • IntriCon Corporation
  • 1260 Red Fox Road
  • Arden Hills
  • Minnesota
  • 55112
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IINNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDJan 1968
SLJDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1968

Biography

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company oper ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 23:54
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.